How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.


EGFL7 and antagonists from University Hospital Frankfurt

Organization name

INNOVECTIS Gesellschaft für Innovations-Dienstleistungen mbH



Scientists from the University Hospital of Frankfurt Main prove for the first time, that the signalling protein EGFL7 binds to notch receptors and regulates the self-renewal of neural stem cells.

Therefore, EGFL7, EGFL7 antagonists and EGFL7 antibodies can be used to grow specialised cells and tissues from neural stem cells and to treat lesions and neurodegenerative diseases of the central nervous system.


So far, EGFL7 (also known as zneu1, VE-statin or notch4 like protein) was shown to be an important modulator of blood vessel formation. The 30 kDa protein is secreted by endothelial cells and effects smooth muscle cells and embryonic fibroblasts. The signalling pathways triggered by EGFL7 and especially receptors that specifically bind EGFL7 are barely known.


Using different binding studies it has been shown that EGFL7 binds to notch receptors and influences their activity. The signalling pathways of the highly conserved notch receptors regulate different development processes, e.g. neurogenesis. Consistently, experiments using murine neurospheres proved that EGFL7 and EGFL7 antagonists influence the proliferation of these cells and play an important role in self renewal.


  • Regulating the development of neural stem cells to grow differentiated cells and tissues
  • Treatment of lesions and neurodegenerative diseases of the central nervous system
  • Modification of learning and memory processes

Project Status

Experiments in cell culture and mouse models showed promising results.

A German patent application is filed. An international application based on the PCT regulations is filed.

Owner of the patent is the Johann Wolfgang Goethe-University Frankfurt am Main.

Licensing or assignment of the technology is possible as well as a cooperation for further development of the invention.


To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.


latest entries